English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., et al. (2012). Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine, 18(2), 221-223. doi:10.1038/nm.2609.

Item is

Files

show Files
hide Files
:
Montagut.pdf (Publisher version), 529KB
 
File Permalink:
-
Name:
Montagut.pdf
Description:
-
Visibility:
Restricted (Max Planck Institute for Molecular Genetics, MBMG; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
2012
Copyright Info:
Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
License:
-

Locators

show

Creators

show
hide
 Creators:
Montagut, C., Author
Dalmases, A., Author
Bellosillo, B., Author
Crespo, M., Author
Pairet, S., Author
Iglesias, M., Author
Salido, M., Author
Gallen, M., Author
Marsters, S., Author
Tsai, S. P., Author
Minoche, A., Author
Seshagiri, S., Author
Serrano, S., Author
Himmelbauer, Heinz1, Author              
Bellmunt, J., Author
Rovira, A., Author
Settleman, J., Author
Bosch, F., Author
Albanell, J., Author
Affiliations:
1Dept. of Vertebrate Genomics (Head: Hans Lehrach), Max Planck Institute for Molecular Genetics, Max Planck Society, Ihnestr. 63-74, Berlin, Germany, ou_1433550              

Content

show
hide
Free keywords: Antibodies, Monoclonal/*therapeutic use Antineoplastic Agents/*therapeutic use Cell Line, Tumor Colorectal Neoplasms/*drug therapy/genetics Drug Resistance, Neoplasm/*genetics Epitopes/genetics Humans Mutation, Missense/genetics Quinazolines/therapeutic use Receptor, Epidermal Growth Factor/*genetics
 Abstract: Antibodies against epidermal growth factor receptor (EGFR)--cetuximab and panitumumab--are widely used to treat colorectal cancer. Unfortunately, patients eventually develop resistance to these agents. We describe an acquired EGFR ectodomain mutation (S492R) that prevents cetuximab binding and confers resistance to cetuximab. Cells with this mutation, however, retain binding to and are growth inhibited by panitumumab. Two of ten subjects studied here with disease progression after cetuximab treatment acquired this mutation. A subject with cetuximab resistance harboring the S492R mutation responded to treatment with panitumumab.

Details

show
hide
Language(s): eng - English
 Dates: 2012-07-062011-08-152011-11-152012-01-222012
 Publication Status: Published in print
 Pages: 3
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1038/nm.2609
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Nature Medicine
  Other : Nat. Med.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: New York, NY : Nature Pub. Co.
Pages: - Volume / Issue: 18 (2) Sequence Number: - Start / End Page: 221 - 223 Identifier: ISSN: 1078-8956
CoNE: https://pure.mpg.de/cone/journals/resource/954925606824